Home › NDC Lookup › Ingredients › Triamcinolone Acetonide › 51672-1284-02
Triamcinolone Acetonide 1 mg/g Ointment — NDC 51672-1284-02 package photo

Triamcinolone Acetonide 1 mg/g Ointment

by Sun Pharmaceutical Industries, Inc. · 1 TUBE in 1 CARTON (51672-1284-2) / 30 g in 1 TUBE
NDC 51672-1284-02
🏷️ FDA NDC (as labeled) 51672-1284-2 billing pads the package segment with a zero
This package
Contains30 g in 1 tube Cost per g$0.1216 NADAC Per package$3.65 / 30 g Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.2759/unit · Part D plans $0.3820/unit — full pricing hub ↓
Also comes in: 15 g 51672-1284-01 80 g 51672-1284-08
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Triamcinolone Acetonide (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Sep 28, 2023 — Presence of Particulate Matter: A product complaint of a piece of glass was identified in a vial. The piece of glass appears to be roughly 1 cm x 0.5 cm inside the vial. (Eugia US LLC) · FDA recall D-0041-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

🆔 Identity & classification

FDA NDC (as labeled) 51672-1284-2
Product NDC 51672-1284
11-digit billing NDC 51672128402
NCPDP billing unit GM — per gram (weight)
RxCUI 1085636
UNII F446C597KA
Application # ANDA040037
SPL Set ID 6b4a9a08-f436-4f33-a940-a97c727788f9
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1994-09-30
Route TOPICAL
Dosage form OINTMENT
Substance TRIAMCINOLONE ACETONIDE
GPI-14 90550085104210
GPI class Triamcinolone Acetonide
GCN Seq No 007597
GCN 31242
HICL code 002891
Ingredient (HICL) Triamcinolone Acetonide
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5P
Therapeutic class — specific (HIC3) Topical Anti-Inflammatory Steroidal
AHFS code 48:10.08.00
AHFS class Corticosteroids (Respiratory Tract)
FDB label name TRIAMCINOLONE 0.1% OINTMENT
FDB brand name Triamcinolone Acetonide
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AT · RLD · RS
Why two NDCs? The FDA registers this code as 51672-1284-2 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 51672-1284-02. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids for local oral treatment, Corticosteroids, Corticosteroids, moderately potent (group II)
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerSun Pharmaceutical Industries, Inc.
Application holderSUN PHARMA CANADA INC
FDA applicationANDA040037 (ANDA)
Labeler code51672
First marketedSep 1994
Product typeHuman Prescription Drug
Portfolio889 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name TRIAMCINOLONE 0.1% OINTMENT Ingredient Triamcinolone Acetonide
📗 Our plain-language guide HelloPharmacist
  • Yes, intra-articular triamcinolone is specifically approved to give short-term relief for knee arthritis, gout flares, bursitis, and similar joint conditions. The extended-release...
  • I'm getting a triamcinolone injection in my knee. Will it actually help, and how long does it last?
  • That's a really important thing to flag with your doctor before your injection or prescription. Triamcinolone can raise blood sugar — even in people whose diabetes is well-controll...
  • I have diabetes. Should I be worried about using triamcinolone?
📖 Read our full Triamcinolone guide →
8
Nutrient depletion considerations

Triamcinolone Acetonide may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Triamcinolone Acetonide nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII C9H2L21V7U
    A fat derived from coconut or palm oil containing shorter fatty acid chains. It serves as a solvent and carrier to help dissolve or suspend active ingredients, improving absorption and stability in liquid formulations.
  • UNII A2I8C7HI9T
    Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
  • UNII 4T6H12BN9U
    Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.
  • UNII Z8IX2SC1OH
    Propylparaben is a chemical preservative used to prevent bacterial and fungal growth in medicines and personal care products. It helps extend shelf life and maintain product safety during storage.

4 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.122 $3.65 / 30 g
Medicaid paysCMS SDUD · 12 mo $0.2759 $8.28 / 30 g
Medicare drug plans payPart D · Q2 2026 $0.3820 $11.46 / 30 g
NADAC price history (per g) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $0.170 $0.122
▼ Down 28% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Triamcinolone Acetonide 1 mg/g 45802-0064-05 Padagis 454 g $0.028 AT Availability likely save 77%
Triamcinolone Acetonide 1 mg/g 45802-0055-05 Padagis 454 g $0.035 AT Availability likely save 71%
Triamcinolone Acetonide 1 mg/g 00713-0225-15 Cosette 1 tube $0.100 AT Discontinued save 18%
Triamcinolone Acetonide 1 mg/g 16714-0986-01 NorthStar 1 tube $0.100 AT Availability likely save 18%
Triamcinolone Acetonide 1 mg/g 33342-0329-15 Macleods 1 tube $0.100 AT Availability likely save 18%
Triamcinolone Acetonide 1 mg/g 67877-0251-15 Ascend 15 g $0.100 AT Availability likely save 18%
Triamcinolone Acetonide 1 mg/g 71656-0042-15 Saptalis 1 tube $0.100 AT Availability likely save 18%
Triamcinolone Acetonide 1 mg/g 21922-0062-04 Encube 1 tube $0.100 AT Availability likely save 18%
Triamcinolone Acetonide 1 mg/g 51672-1282-01 Sun 1 tube $0.100 AT Availability likely save 18%
triamcinolone acetonide 1 mg/g 00168-0004-15 E. 1 tube $0.100 AT Availability likely save 18%
Triamcinolone Acetonide 1 mg/g 00168-0006-15 E. 15 g $0.119 AT Availability likely save 2%
Triamcinolone Acetonide 1 mg/g 00713-0228-15 Cosette 1 tube $0.119 AT Availability likely save 2%
Triamcinolone acetonide 1 mg/g 16714-0276-01 NorthStar 1 tube $0.119 AT Availability likely save 2%
Triamcinolone Acetonide 1 mg/g 21922-0063-04 Encube 1 tube $0.119 AT Availability likely save 2%
Triamcinolone acetonide 1 mg/g 33342-0333-15 Macleods 1 tube $0.119 AT Availability likely save 2%
Triamcinolone Acetonide 1 mg/gthis 51672-1284-02 Sun 1 tube $0.122 AT Availability likely —
Triamcinolone Acetonide 1 mg/g 64980-0320-05 Rising 1 tube $2.686 AT Availability likely +2109%
Triamcinolone Acetonide 1 mg/g 50090-2244-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 50090-3508-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 50090-4761-00 A-S 1 tube — AT FDA listed —
Triamcinolone acetonide 1 mg/g 50090-6978-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 50090-7679-00 A-S 1 tube — AT FDA listed —
Triasil 59088-0730-00 PureTek 1 kit — — FDA listed —
Triamcinolone Acetonide 1 mg/g 61919-0619-15 DIRECTRX 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 67296-1927-01 RedpharmDrug 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-1872-08 NuCare 80 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 68071-2362-05 NuCare 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-4286-05 NuCare 15 g — — FDA listed —
Triamcinolone Acetonide 1 mg/g 68462-0797-17 Glenmark 1 tube — — FDA listed —
Triamcinolone Acetonide 1 mg/g 70518-3689-00 REMEDYREPACK 1 tube — AT FDA listed —
Triamcinolone Acetonide 5 mg/g 71205-0033-15 Proficient 1 tube — — FDA listed —
Triamcinolone Acetonide 1 mg/g 71205-0108-15 Proficient 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72162-2336-02 Bryant 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 76420-0361-00 Asclemed 454 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 82804-0079-30 Proficient 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 63187-0053-15 Proficient 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 71205-0627-15 Proficient 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 76420-0203-15 Asclemed 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 50090-6547-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 50090-6566-00 A-S 454 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 63187-0870-15 Proficient 1 tube — — FDA listed —
Triamcinolone acetonide 1 mg/g 63629-8779-01 Bryant 30 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68462-0131-17 Glenmark 1 tube — — FDA listed —
Triamcinolone acetonide 1 mg/g 71335-2211-01 Bryant 454 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 50090-2106-00 A-S 30000 mg — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-2736-03 NuCare 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72189-0277-15 Direct_Rx 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 63629-9573-01 Bryant 454 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-3852-08 NuCare 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68788-7797-01 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 71335-2712-01 Bryant 454 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 63187-0025-15 Proficient 15 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 63629-8778-01 Bryant 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-4383-05 NuCare 15 g — — FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-4945-05 NuCare 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68788-8356-00 Preferred 1 tube — AT FDA listed —
Triamcinolone acetonide 1 mg/g 72162-1832-03 Bryant 30 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72189-0571-80 Direct_rx 80 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 82804-0145-30 Proficient 1 tube — AT FDA listed —
triamcinolone acetonide 1 mg/g 68071-4391-03 NuCare 30 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 82804-0071-30 Proficient 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72189-0039-80 Direct_Rx 80 g — AT FDA listed —
Kourzeq 1 mg/g 82682-0001-05 MidAmerica 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 61919-0650-15 DIRECTRX 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 63629-9574-01 Bryant 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-3666-03 NuCare 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72162-1386-04 Bryant 1 tube — AT FDA listed —
Triamcinolone acetonide 1 mg/g 50090-0162-00 A-S 80 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 52817-0811-15 TruPharma, 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 66267-0933-80 NuCare 80 g — — FDA listed —
Triamcinolone Acetonide 1 mg/g 70518-1524-00 REMEDYREPACK 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 70518-2403-00 REMEDYREPACK 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 71335-2713-01 Bryant 80 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 76420-0348-00 Asclemed 454 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 63629-8781-01 Bryant 454 g — AT FDA listed —
Triderm 1 mg/g 00316-0170-01 Crown 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-3982-05 NuCare 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68788-8350-01 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 70518-2285-00 REMEDYREPACK 1 tube — AT FDA listed —
Triamcinolone acetonide 1 mg/g 50090-0228-00 A-S 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 61919-0234-30 Direct_Rx 30 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 63629-8780-01 Bryant 80 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68788-8753-01 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 70518-2963-00 REMEDYREPACK 1 tube — AT Discontinued —
Triamcinolone Acetonide 1 mg/g 72189-0670-30 Direct_rx 30 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68788-8386-05 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 70518-4527-00 REMEDYREPACK 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 85766-0244-15 Sportpharm 1 tube — AT FDA listed —
Triamcinolone acetonide 1 mg/g 67296-2327-01 Redpharm 1 tube — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
1994
On the market since
Sep 1994
📍
2026
Currently FDA-listed
32 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 51672-1284-02, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
148.1K
Units reimbursed last 4 qtrs
5.7M
Gross reimbursed last 4 qtrs
$1.56M
Avg / prescription
$10.54
Avg / unit
$0.2759
Latest quarter Q4 2025
20.5KRx
Medicaid pays / g
$0.2759
gross reimbursed
vs
NADAC / g
$0.1216
acquisition cost
=
Spread
+$0.1543
+127% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
41% FFS 59% MCO
Fee-for-service · 60,677 Rx Managed care · 87,374 Rx
State Medicaid map
Alaska: 6,720 units · 917 per 100k residents AK Maine: 20,700 units · 1,484 per 100k residents ME Washington: 73,495 units · 941 per 100k residents WA Idaho: 21,120 units · 1,075 per 100k residents ID Montana: 12,420 units · 1,097 per 100k residents MT North Dakota: 3,660 units · 467 per 100k residents ND Minnesota: 143,976 units · 2,510 per 100k residents MN Wisconsin: 223,720 units · 3,785 per 100k residents WI Michigan: 219,240 units · 2,184 per 100k residents MI New York: 534,355 units · 2,730 per 100k residents NY Vermont: 10,635 units · 1,644 per 100k residents VT New Hampshire: 10,860 units · 775 per 100k residents NH Oregon: 36,765 units · 869 per 100k residents OR Nevada: 55,170 units · 1,727 per 100k residents NV Wyoming: 4,350 units · 745 per 100k residents WY South Dakota: 11,025 units · 1,200 per 100k residents SD Iowa: 74,985 units · 2,338 per 100k residents IA Illinois: 393,391 units · 3,135 per 100k residents IL Indiana: 58,048 units · 846 per 100k residents IN Ohio: 136,715 units · 1,160 per 100k residents OH Pennsylvania: 142,533 units · 1,100 per 100k residents PA New Jersey: 165,066 units · 1,777 per 100k residents NJ Massachusetts: 72,283 units · 1,032 per 100k residents MA California: 703,793 units · 1,806 per 100k residents CA Utah: 24,840 units · 727 per 100k residents UT Colorado: 65,640 units · 1,117 per 100k residents CO Nebraska: 44,655 units · 2,258 per 100k residents NE Missouri: 163,400 units · 2,637 per 100k residents MO Kentucky: 81,405 units · 1,799 per 100k residents KY West Virginia: 12,000 units · 678 per 100k residents WV Virginia: 91,765 units · 1,053 per 100k residents VA Maryland: 159,847 units · 2,587 per 100k residents MD Connecticut: 77,460 units · 2,142 per 100k residents CT Rhode Island: 17,970 units · 1,641 per 100k residents RI Arizona: 80,660 units · 1,085 per 100k residents AZ New Mexico: 76,185 units · 3,604 per 100k residents NM Kansas: 36,600 units · 1,245 per 100k residents KS Arkansas: 52,185 units · 1,701 per 100k residents AR Tennessee: 200,900 units · 2,819 per 100k residents TN North Carolina: 298,973 units · 2,759 per 100k residents NC South Carolina: 50,000 units · 931 per 100k residents SC Delaware: 48,930 units · 4,746 per 100k residents DE Oklahoma: 74,420 units · 1,836 per 100k residents OK Louisiana: 143,935 units · 3,147 per 100k residents LA Mississippi: 63,480 units · 2,159 per 100k residents MS Alabama: 102,489 units · 2,006 per 100k residents AL Georgia: 129,624 units · 1,175 per 100k residents GA D.C.: 50,171 units · 7,389 per 100k residents DC Hawaii: 2,580 units · 180 per 100k residents HI Texas: 221,940 units · 728 per 100k residents TX Florida: 127,155 units · 562 per 100k residents FL
Units reimbursed · per 100k residents
1807,389
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 D.C. 7,389 /100k
2 Delaware 4,746 /100k
3 Wisconsin 3,785 /100k
4 New Mexico 3,604 /100k
5 Louisiana 3,147 /100k
6 Illinois 3,135 /100k
7 Tennessee 2,819 /100k
8 North Carolina 2,759 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube this page51672-1284-02 148,051 Rx · $1,560,033
1 tube51672-1284-08 7,208 Rx · $131,044
1 tube51672-1284-01 6,762 Rx · $58,884
Drug total (last 4 qtrs): 162,021 Rx · 6,443,802 units · $1,749,960 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Triamcinolone Acetonide — the program that covers self-administered drugs. 22 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Triamcinolone Acetonide. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$17.79M
Claims incl. refills
1.7M
Beneficiaries
1.4M
Spend / beneficiary
$13.01
Spend / claim
$10.45
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Triamcinolone Acetonide — the ingredient across all brands.

Top reported reactions

Pruritus2,650
Rash2,534
Pain2,232
Fatigue2,133
Nausea2,043
Headache1,916
Condition Aggravated1,747

Reporter sex

31,697 reports
Male · 34%
Female · 66%
Unknown · 0%

Serious outcomes

Hospitalization6,577
Death3,076
Disabling2,415
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 4,201 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
51672-1284-01 1 TUBE in 1 CARTON (51672-1284-1) / 15 g in 1 TUBE $0.1190 / g $1.79 1994-09-30 Active
51672-1284-02 You're viewing this 1 TUBE in 1 CARTON (51672-1284-2) / 30 g in 1 TUBE $0.1216 / g $3.65 2016-10-26 Active
51672-1284-08 1 TUBE in 1 CARTON (51672-1284-8) / 80 g in 1 TUBE $0.0655 / g $5.24 1994-09-30 Active

Per g, this pack runs about 86% above the cheapest pack (NDC 51672-1284-08, $0.0655 vs $0.1216 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 91% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in NDC 51672-1284-02?
NDC 51672-1284-02 is listed by the FDA — 1 tube in 1 carton / 30 g in 1 tube.
What NDC number is used to bill for this package of Triamcinolone Acetonide 1 mg/g Ointment?
Bill NDC 51672-1284-02 — the 11-digit billing format is 51672128402. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients
🎯 Indications and Usage 20 words ▾

INDICATIONS AND USAGE Triamcinolone Acetonide Ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

⏱️ Dosage and Administration 177 words ▾

DOSAGE AND ADMINISTRATION Apply a thin film of the 0.1% Triamcinolone Acetonide Ointment, as appropriate, to the affected area two to three times daily. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Apply a thin film of ointment to the lesion, cover with a pliable nonporous film, and seal the edges.

If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply Triamcinolone Acetonide Ointment under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion).

When utilizing the 12-hour occlusion regimen, additional ointment should be applied, without occlusion, during the day. Reapplication is essential at each dressing change. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

⛔ Contraindications 21 words ▾

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

🤒 Adverse Reactions 60 words ▾

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.

🤰 Pregnancy 96 words ▾

Pregnancy Teratogenic Effects Pregnancy Category C Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on the teratogenic effects from topically applied corticosteroids.

Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

🧒 Pediatric Use 114 words ▾

Pediatric Use Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.

Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

🆘 Overdosage 18 words ▾

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS, General ).

🧬 Clinical Pharmacology 192 words ▾

CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.

There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin.

Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION ).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.

Some of the topical corticosteroids and their metabolites are also excreted into the bile.

📦 How Supplied / Storage and Handling 37 words ▾

HOW SUPPLIED Triamcinolone Acetonide Ointment USP, 0.1% is supplied in 15 g (NDC 51672-1284-1), 30 g (NDC 51672-1284-2), and 80 g (NDC 51672-1284-8) tubes. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

📦 Storage and Handling 13 words ▾

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

📋 Description 81 words ▾

DESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents. The steroids in this class include triamcinolone acetonide. Triamcinolone acetonide is designated chemically as pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11β,16α)-.

The structural formula is: Molecular Weight: 434.51 Molecular Formula: C 24 H 31 FO 6 Each gram of Triamcinolone Acetonide Ointment USP, 0.1% contains 1 mg triamcinolone acetonide, in an ointment base of fractionated coconut oil and white petrolatum, with methylparaben and propylparaben as preservatives. Chemical Structure

💬 Information for Patients 121 words ▾

Information for Patients Patients using topical corticosteroids should receive the following information and instructions: This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.

Patients should be advised not to use this medication for any disorder other than for which it was prescribed. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician. Patients should report any signs of local adverse reactions especially under occlusive dressing.

Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 51672-1282-01 · Sun 51672-1289-01 · Sun →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.